Cover Image
市場調查報告書

腦脊髓炎:開發中產品分析

Encephalomyelitis - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 271844
出版日期 內容資訊 英文 42 Pages
訂單完成後即時交付
價格
Back to Top
腦脊髓炎:開發中產品分析 Encephalomyelitis - Pipeline Review, H1 2017
出版日期: 2017年03月15日 內容資訊: 英文 42 Pages
簡介

腦脊髓炎是腦和脊髓的發炎。一般的原因是感染神經組織的病毒。有頸椎僵直,頭痛,有發熱等徵兆和症狀。

本報告提供腦脊髓炎的治療藥開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

簡介

  • 調查範圍

腦脊髓炎概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

腦脊髓炎:企業開發中的治療藥

腦脊髓炎:大學/機關研究中的治療藥

腦脊髓炎:開發中產品概況

  • 臨床階段的產品
  • 初期階段的產品

腦脊髓炎:企業開發中的產品

腦脊髓炎:大學/機關研究中的產品

腦脊髓炎的治療藥的開發企業

  • Biovista Inc.
  • Effimune SAS
  • Endocyte, Inc.
  • InteKrin Therapeutics, Inc.
  • Io Therapeutics, Inc.
  • Merck & Co., Inc.
  • Momenta Pharmaceuticals, Inc.
  • Sorrento Therapeutics, Inc.

腦脊髓炎:治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • 抗體
  • EC-1496
  • FR-104
  • INT-131
  • IRX-5183
  • JM-4
  • PSA-20
  • SCH-546738
  • 小分子
  • STIB-0201
  • thymulin

腦脊髓炎:最近的開發平台趨勢

腦脊髓炎:暫停中的計劃

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9055IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Encephalomyelitis - Pipeline Review, H1 2017, provides an overview of the Encephalomyelitis (Central Nervous System) pipeline landscape.

Encephalomyelitis is an inflammation of the brain and spinal cord. Encephalomyelitis can be caused by a variety of conditions that lead to irritation of the brain and spinal cord. Among the common causes of encephalomyelitis are viruses which infect the nervous tissues. Signs and symptoms include neck stiffness, headache, and fever. Treatment includes antibiotics and corticosteroids.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Encephalomyelitis - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Encephalomyelitis (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Encephalomyelitis (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Encephalomyelitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in IND/CTA Filed, Preclinical and Discovery stages are 1, 5 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 5 molecules, respectively.

Encephalomyelitis (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Encephalomyelitis (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Encephalomyelitis (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Encephalomyelitis (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Encephalomyelitis (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Encephalomyelitis (Central Nervous System)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Encephalomyelitis (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Encephalomyelitis (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Encephalomyelitis - Overview
  • Encephalomyelitis - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Encephalomyelitis - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Encephalomyelitis - Companies Involved in Therapeutics Development
  • Aurigene Discovery Technologies Ltd
  • Bionure Farma SL
  • Biovista Inc
  • Momenta Pharmaceuticals Inc
  • OSE Immunotherapeutics
  • Philogen SpA
  • Encephalomyelitis - Drug Profiles
  • BN-201 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • FR-104 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • JM-4 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • M-254 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Preimplantation Factor - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • PSA-20 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecule for Chronic Fatigue Syndrome and Myalgic Encephalomyelitis - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecule to Activate NF-E2 Related Factor 2 for Central Nervous System, Metabolic Disorders, Cardiovascular and Ophthalmology - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecule to Agonize ROR-Gamma for Inflammation and Oncology - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Tetravil - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • thymulin - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • WEHI-345 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Encephalomyelitis - Dormant Projects
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Encephalomyelitis, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Encephalomyelitis - Pipeline by Aurigene Discovery Technologies Ltd, H1 2017
  • Encephalomyelitis - Pipeline by Bionure Farma SL, H1 2017
  • Encephalomyelitis - Pipeline by Biovista Inc, H1 2017
  • Encephalomyelitis - Pipeline by Momenta Pharmaceuticals Inc, H1 2017
  • Encephalomyelitis - Pipeline by OSE Immunotherapeutics, H1 2017
  • Encephalomyelitis - Pipeline by Philogen SpA, H1 2017
  • Encephalomyelitis - Dormant Projects, H1 2017

List of Figures

  • Number of Products under Development for Encephalomyelitis, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products by Targets, H1 2017
  • Number of Products by Stage and Targets, H1 2017
  • Number of Products by Mechanism of Actions, H1 2017
  • Number of Products by Stage and Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top